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dTo the Editor: Severe tricuspid regurgitation (TR) is associated with
ncreased morbidity andmortality. In advanced TR stages, right-sided
eart failure, ascites, and congestive hepatopathy increase surgical risk
1); alternative approaches are therefore required.
Transcatheter valve procedures are increasingly applied in clinical
ractice to treat aortic, mitral, and pulmonary valve diseases (2,3). Few
ata are available, however, on percutaneous treatment of the tricuspid
alve regurgitation (TV). The specific approach to implant two valves
n the superior and inferior vena cava (IVC) was originally proposed
y Davidson et al. (4). One human case report described successful
ranscatheter treatment of TR with a customized, self-expanding
eart valve for IVC implantation (5).
Here we describe the feasibility, technical details, and peripro-
edural and short-term outcomes of a novel first-in-man approach
or implantation of the Edwards Sapien XT (approved for the
ortic valve) as IVC valve between the right atrium (RA) and the
epatic vein (i.e., single valve) and in combination with a superior
ena cava (SVC) valve (dual valve). Between August and Septem-
er 2012, we treated 3 patients with severe symptomatic TR at
igh risk for surgical repair. All patients (2 men, 1 woman) had
econdary TR with recurrent right heart failure despite optimal
herapy (including high-dose diuretic regimens) (Table 1). Because
f the presence of defibrillator leads in the SVC, a single valve was
Patients CharacteristicsTable 1 Pati nts Characteristics
Characteristic P
Age (yrs)
Sex
Logistic Euroscore (%)
Clinical Characteristics Baseline
NYHA functional class IV
Peripheral edema 
Ascites 
Echocardiographic right ventricular parameters
Tricuspid annular plane systolic excursion (mm) 11
Right ventricular systolic velocity (cm/s) 7
Maximum tricuspid regurgitation velocity (m/s) 3.4
Hepatic veins (mm) 22
Multislice computed tomographic right ventricular parameters
Right ventricular end-diastolic volume (ml) 179
Right ventricular ejection fraction (%) 59
Right atrial volume (ml) 129
Coronary sinus (mm) 10*Post-intervention values.
NA  not available; NYHA  New York Heart Association.mplanted in the IVC in patients 1 and 2, whereas patient 3 received
ual-valve implantation. Echocardiography and multislice computed
omography (MSCT) were performed to assess disease severity
Table 1, right heart parameters) and to carefully evaluate the
elationship/distance between RA, IVC, and hepatic veins.
hese investigations were repeated after 1 month to evaluate
ost-interventional results. In addition, periprocedural, in-
ospital, and 30-day outcomes were assessed according to Valve
cademic Research Consortium Criteria (VARC). Procedures
ere performed with the patient under general anesthesia, with
uoroscopic and transesophageal echocardiography guidance.
The major challenges to valve implantation in IVC are complex
natomy, a short segment between RA and the ostium of the hepatic
ein, and large diameter of the vena cava. At present, the only suitable
ommercial prosthesis for this percutaneous approach is the Edwards
apien XT (29 mm). The intervention was performed as compas-
ionate treatment. All patients provided written informed consent.
he procedure was performed through the right femoral vein (Ed-
ards expandable 20-F eSheat introducer set; Novaflex delivery
ystem). To guarantee stable placement of the prosthesis, we prepared
landing zone by implanting a self-expanding 30/60-mm Sinus XL
tent in the IVC segment downstream of the RA. To further
ownsize the lumen, we placed a second, shorter stent in the upper
#1 Patient #2 Patient #3
72 71
le Male Male
69.4 41.5
30 Days* Baseline 30 Days* Baseline 30 Days*
II IV III III II
    
    
16 11 15 15 16
8.5 12 10 11 NA
3.2 2.8 2.8 2.0 1.7
9 16 15 16 12
167 231 209 348 267
61 41 42 44 43
118 284 198 201 189
10 11 9 11 11atient
72
Fema
47.0
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May 7, 2013:1929–34part of the first stent. The Edwards Sapien XT valve mounted on the
Novaflex delivery system was then deployed (Figs. 1A and 1B). In
patient 3, we performed the dual-valve procedure: in addition to IVC,
an SVC prosthesis was also implanted after positioning of a self-
expanding stent to reduce the risk of vessel wall damage and/or
rupture (Figs. 1C and 1D). Subsequently, the second prosthesis was
implanted in the IVC by the same technique as previously described.
Right ventricular angiography and echocardiography confirmed intact
valve function without paravalvular leakage and without regurgitation
in any case. There were no periprocedural or in-hospital complica-
tions. Peri-interventionally, the patients received unfractionated hep-
arin and thereafter oral anticoagulation therapy.
At 30 days there were no events according to VARC criteria.
Valve function remained excellent throughout the follow-up pe-
riod. No valve regurgitation or leakage was detected. We observed
free drainage of hepatic veins with only antegrade flow into the
IVC. As shown in Table 1, all patients improved by at least 1
NYHA class, and signs of right heart congestion clearly decreased.
It is noteworthy that in all 3 patients, RV function improved and
that right ventricular and RA volumes as well as the diameters of
Figure 1 Transfemoral Caval Valve Implantation (Edwards Sapi
Fluoroscopy (A) and multisclice computed tomography (B) show single-valve appro
(C and D) Dual valve approach with a second valve in the superior vena cava.the hepatic veins decreased.In summary, percutaneous single or dual caval prosthesis im-
plantation with the Edwards Sapien XT for severe TR is feasible
and safe. It is, however, cost-intensive.
The major therapeutic effect of this procedure appears to be
reduction of hepatic, abdominal, and peripheral venous congestion
leading to amelioration of right heart failure. To avoid right heart
failure by increased preload, we believe that preserved right ventricular
function is a prerequisite for the success of the procedure, particularly with
respect to the dual-valve approach. Because these valves are implanted in
the low-pressure system, lifelong anticoagulation will be required.
Despite our very promising short-term results, further larger
controlled trials are necessary to determine the impact of this novel
interventional approach on morbidity and mortality in patients
with severe TR.
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Letter to the Editor
Mendelian Randomization
Estimates May Be Inflated
Ference et al. (1), using a Mendelian randomization approach,
show that the genetic effect of a unit change in low-density
lipoprotein (LDL) on coronary heart disease (CHD) is much
larger than the increase in risk per unit LDL seen prospectively in
cohort studies or the similar-sized decrease in risk per unit LDL
seen with effective interventions. The authors ascribe this differ-
ence to the lifelong effects of low LDL and suggest that earlier
intervention to reduce LDL could be beneficial. This is quite
possible. However, the Mendelian randomization estimate given
for the genetic effect of a unit change in LDL on CHD depends
on the assumption that the association of genetic variants with
LDL is constant across life or changes consistently with the
association of genetic variants with CHD. If some aspect of aging
or ill health reduced only the genetic association with LDL, the
genetic effect of a unit change in LDL on CHD would be
overstated (2) because the Mendelian randomization genetic effect
of LDL on CHD was estimated as the association of genetic
variants with CHD divided by the association of genetic variants
with LDL. Most of the studies providing the estimate of genetic
variants with LDL concern middle-aged people (1), in whomLDL levels may be affected by factors such as aging, ill health,
treatment, or body mass index, potentially attenuating the true
association of genetic variants with LDL. Few studies have
examined whether genetic associations with LDL vary with aging
and ill health, but evidence exists that shows the association of
some of the relevant genetic variants with LDL can vary substan-
tially with age (3,4), with weaker associations seen in older people.
Thus, the findings reported may not be inconsistent with the
effects of a unit change in LDL on CHD seen in cohort studies
and randomized control trials. Instead of indicating the life-long
effects of LDL, these findings may be the result of reverse
causality weakening the genetic association with specifically
LDL and thereby inflating the estimate.
More generally, this study illustrates the difficulty with inter-
preting such as Mendelian randomization estimates. Mendelian
randomization studies are most suitable for refuting causality
rather than establishing the exact size of a causal effect. First, such
a Mendelian randomization estimate will only indicate the true
size of a causal effect if the level of over- or under-estimation of the
genetic associations with the exposure and outcome are similar
(and nondifferential). If the observed genetic association with the
exposure is more understated than that with the outcome, then the
estimate may be too large. Conversely, if the observed genetic
association with the exposure is less understated than that with the
outcome, then the estimate may be too small. Second, an exposure
could appear to be causal in a Mendelian randomization study if it
were a marker of an intermediate factor between genetic variants
and exposure that also caused the exposure and outcome. As such,
Mendelian randomization estimates should be interpreted as
hypothesis testing, that is, able to disprove a postulated causal
effect, rather than indicating the size or existence of a postulated
causal effect.
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Reply
We agree with Dr. Schooling and colleagues that interpreting the
magnitude of the association between a modifiable exposure such
